EP Patent

EP4370120A1 — Methods of treating fabry disease in pediatric patients

Assigned to Amicus Therapeutics Inc · Expires 2024-05-22 · 2y expired

What this patent protects

Provided are methods for the treatment of Fabry disease in adolescent patient.

USPTO Abstract

Provided are methods for the treatment of Fabry disease in adolescent patient.

Drugs covered by this patent

migalastat-hydrochloride (MIGALASTAT HYDROCHLORIDE)

Patent Metadata

Patent number: EP4370120A1
Jurisdiction: EP
Classification: —
Expires: 2024-05-22
Drug substance claim: No
Drug product claim: No
Assignee: Amicus Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.